

No: *12*.../TKKT

Ho Chi Minh City, April 18, 2025

To: - State Securities Commission of Vietnam
- Hanoi Stock Exchange

Subject: *Explanation for Business Performance in the first quarter of 2025 with a Difference of Over 10% Compared to the first quarter of 2024*

Pursuant to Circular No. 96/2020/TT-BTC guiding information disclosure on the securities market, Mekophar Chemical Pharmaceutical Joint Stock Company (Stock Code: MKP) hereby explains the business performance in the first quarter of 2025, which differs by more than 10% compared to the first quarter of 2024 as follows:

Performance Results of Q1 2025 Compared to Q1 2024 – Separate Financial Statements:

Indicator	Q1 2025	Q1 2024	Difference	(%)
Revenue	229,527,884,263	243,165,829,133	- 13,637,944,870	-5.6%
Cost of Goods Sold	167,832,547,697	157,677,796,502	10,154,751,195	6.4%
Selling Expenses	30,982,842,786	26,130,033,749	4,852,809,037	18.6%
Administrative Expenses	30,513,920,318	28,131,751,178	2,382,169,140	8.5%
Net Profit After Tax	- 13,452,585,160	14,219,702,486	- 27,672,287,646	-194.6%

Reason: Net profit after tax in the first quarter of 2025 decreased by 194.6% mainly due to a decline in revenue, while selling expenses and general & administrative expenses rose significantly as a result of increased input prices.

This information has been published on the Company's website at: <https://mekophar.com/> in the "Investor Relations" section.

The Company affirms that the information provided is accurate and takes full responsibility for the disclosed content.

Recipient:

- As above
- Archive

GENERAL DIRECTOR *AN*


Pharm. Huỳnh Thị Lan